SecBot SecBot
6-K ·Filed May 26, 2026

AZN

ASTRAZENECA PLC
BULLISH
Impact 7/10
Horizonweeks Processed5mo ago SEC0001654954-26-005306
Notable filing: 6-K
Actionable Insight ▲ Bullish

The CHMP positive opinion is a strong catalyst for AZN, reinforcing Enhertu's leadership in the ADC space and expanding its label in a major market. Monitor for formal EC approval (typically within 2-3 months of CHMP opinion) and subsequent launch. The ongoing EU reviews for DESTINY-Breast09 and DESTINY-Breast05 provide additional near-term pipeline catalysts.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$187.11
T+0 close · May 26, 2026 · via day close
Latest settled
−11.91%
T+60 · $164.83
Vs SPY
−14.37%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 26 $187.11entry
  2. T+1 · 6mo ago −0.80%α −0.81% · $185.62
  3. T+5 · 6mo ago −5.19%α −6.41% · $177.39
  4. T+20 · 5mo ago −3.25%α −0.99% · $181.02
  5. T+60 · 3mo ago −11.91%α −14.37% · $164.83

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

AstraZeneca and Daiichi Sankyo's Enhertu received a positive CHMP opinion recommending EU approval as a tumor-agnostic monotherapy for previously treated HER2-positive (IHC 3+) metastatic solid tumors. If approved, it would be the first HER2-directed therapy and ADC with a tumor-agnostic indication in the EU, based on Phase II data showing clinically meaningful responses across multiple tumor types. This expands Enhertu's addressable market in the EU beyond its current approvals in breast, lung, and gastric cancers.

Key Facts

  • CHMP recommended Enhertu for EU approval as monotherapy for adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior treatment and have no satisfactory treatment options.
  • If approved, Enhertu would become the first HER2-directed therapy and antibody drug conjugate to receive a tumor-agnostic indication in the EU.
  • The recommendation is based on data from three Phase II trials: DESTINY-PanTumor02 (ORR 51.4%, median DOR 14.2 months in IHC 3+ tumors, n=111), DESTINY-Lung01 (ORR 52.9%, median DOR 6.9 months in IHC 3+ NSCLC, n=17), and DESTINY-CRC02 (ORR 46.9%, median DOR 5.5 months in IHC 3+ colorectal cancer, n=64).
  • Enhertu already has a tumor-agnostic indication in the US and other countries based on the DESTINY-PanTumor02 trial.
  • Additional EU regulatory submissions are under review for Enhertu in combination with pertuzumab for 1st-line HER2+ breast cancer (DESTINY-Breast09) and for HER2+ breast cancer with residual invasive disease after neoadjuvant treatment (DESTINY-Breast05).

Financial Impact

Expands Enhertu's addressable EU market to include all HER2-positive (IHC 3+) solid tumors, potentially adding hundreds of millions in annual revenue. Enhertu is already approved in >95 countries for breast cancer and >75 for NSCLC; this tumor-agnostic label opens a new patient population across biliary tract, bladder, cervical, endometrial, ovarian, pancreatic, and other tumors.

revenuemarket share

Risk Factors

  • Final European Commission approval is not guaranteed and could be delayed or conditional.
  • Tumor-agnostic approval is based on Phase II data; confirmatory trials may be required for full approval.
  • Competition from other HER2-directed ADCs and therapies could limit market share.
  • Enhertu's safety profile includes interstitial lung disease risk, which could impact real-world adoption.

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (36 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001654954-26-005306
Document: 0001654954-26-005306-index-headers.html0001654954-26-005306
Document: 0001654954-26-005306-index.html0001654954-26-005306
Document: 0001654954-26-005306.txt0001654954-26-005306

Track record

77 reports on AZN

Performance horizon

19 of 37 bullish or bearish reports moved the stock their way by T+5. Best: +20.72% at T+60 after the Aug 17, 2026 report. 29 of 37 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Bullish 6/10 Entry price pending
  2. Nov 16, 2026today 6-K Bullish 6/10 Entry $185.55 Now $184.02 −0.82% settles Nov 23
  3. Nov 16, 2026today 6-K Bullish 6/10 Entry $185.31 Now $184.02 −0.70% settles Nov 23
  4. Nov 16, 2026today 6-K Bullish 5/10 Entry $185.09 Now $184.02 −0.58% settles Nov 23
  5. Nov 4, 202612d ago Institutional Cluster Mixed 3/10 Entry $186.85 to $184.38 Now $184.02 −1.51% ▼ −1.32% −4.61% vs SPY
  6. Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
  7. Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.02 −1.37% ▲ +1.51% +1.43% vs SPY
  8. Oct 30, 202617d ago 6-K Neutral 5/10 Entry $186.65 to $186.43 Now $184.02 −1.41% ▼ −0.12% +2.59% vs SPY
  9. Oct 27, 202620d ago 6-K Bullish 5/10 Entry $170.08 to $183.88 Now $184.02 +8.20% ▲ +8.11% +10.10% vs SPY
  10. Oct 22, 202625d ago 6-K Bullish 6/10 Entry $172.57 to $173.46 Now $184.02 +6.63% ▲ +0.51% −0.19% vs SPY
Showing 10 of 77

US Market Status

Market Closed · Opens Wed (11h 54m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 26, 2026